HEK-293 cells were transiently transfected with expression plasmids encoding Myc-tagged EGFR and V5-tagged PHD2 variants (wt PHD2, catalytically inactive PHD2 (mut H374A), PHD2 Δ1-139aa, and PHD2 Δ208-426aa) to investigate the binding preferences of PHD2 and EGFR. Immunoprecipitations were carried out as described [53]. Cells were harvested 48 h post-transfection, washed twice with ice-cold phosphate buffered saline (PBS) and lysed as described. For immunoprecipitation in the presence of EGF and/or catalytic inhibitors of EGFR and PHD2, cells were pre-treated with AG 1478 (1 mM) or DMOG (2 mM) for 6 h prior to vehicle/EGF (100 ng/ml) treatment for 10 min, then cells were lysed. Aliquots of cleared HEK-293 cell lysates containing 1 mg of total protein were mixed with protein G Sepharose beads (GE Healthcare) and Myc-tagged EGFR was immunoprecipitated with the Myc-Tag antibody (Cell Signaling #2278) or V5-tagged PHD2 proteins were immunoprecipitated with the V5 Tag antibody (Thermo Fisher, R960-25) at 4°C overnight. The next day the beads were washed 5 times with lysis buffer, immune complexes were then resolved on SDS-PAGE 7.5% or 12.5%, respectively and analyzed as below with antibodies against the Myc and V5 epitope. Lysates from EGF and/or inhibitor-treated cells were checked for phosphorylation of EGFR and accumulation of HIF-1α as a verification of the inhibition of PHD2 and EGFR.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.